Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
All paxlovid studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPaxlovidPaxlovid (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes       

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/​Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/​Ritonavir

Pfizer, NCT05567952, NCT05567952
Oct 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Recovery 8% Improvement Relative Risk Reduction in viral load 18% Viral clearance 19% Paxlovid  Pfizer et al.  LATE TREATMENT  DB RCT Is late treatment with paxlovid beneficial for COVID-19? Double-blind RCT 436 patients in the USA Improved viral clearance with paxlovid (p=0.0004) c19early.org Pfizer, NCT05567952, October 2024 Favorspaxlovid Favorscontrol 0 0.5 1 1.5 2+
RCT 436 patients with post-paxlovid rebound showing improved viral load at day 5 but no significant difference in recovery time or viral clearance with repeated paxlovid treatment vs. placebo/ritonavir.
risk of no recovery, 7.9% lower, HR 0.92, p = 0.52, treatment 186, control 99, inverted to make HR<1 favor treatment, Cox proportional hazards, day 28.
relative reduction in viral load, 18.2% better, RR 0.82, p < 0.001, treatment 218, control 113, day 5.
risk of no viral clearance, 19.0% lower, HR 0.81, p = 0.07, treatment 223, control 115, inverted to make HR<1 favor treatment, time to two consecutive negative RAT results at least 24 hours apart, Cox proportional hazards, day 28.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pfizer et al., 8 Oct 2024, Double Blind Randomized Controlled Trial, USA, preprint, 1 author, trial NCT05567952 (history). Contact: ClinicalTrials.gov_Inquiries@pfizer.com.
This PaperPaxlovidAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit